Board of Directors
John H. Tucker is the chief executive officer of scPharmaceuticals. Prior to scPharmaceuticals, Mr. Tucker served as chief executive officer of Alcresta, developer of enzyme-based products for patients with acute and chronic diseases. While at Alcresta he led regulatory and financing strategies leading to its first product approval and increased valuation. Prior to Alcresta, he served as senior vice president and chief commercial officer of Incline Therapeutics, a hospital-focused specialty pharmaceutical company. There, he developed and drove the overall commercial strategy in support of the company’s lead product, IONSYS™, resulting in a $390 million purchase of Incline by The Medicines Company. He joined Incline from AMAG Pharmaceuticals, where he was senior vice president, commercial operations, responsible for all sales and marketing activities for the company. Previously, as president, U.S. operations at Basilea Pharmaceuticals, Mr. Tucker developed the strategy and organization for the planned launch of a hospital-focused product and led the company’s commercial development team. Prior to Basilea, Mr. Tucker was executive vice president, sales and marketing at Indevus Pharmaceuticals. Earlier in his career, he held a variety of both hospital and retail-based sales and marketing positions with increasing levels of responsibility at Ortho-McNeil Pharmaceuticals, ALZA Corporation, VIVUS and UCB Pharma. Mr. Tucker holds a B.A. from Plymouth State College and an MBA from New Hampshire College.
Mette Kirstine was previously co-founder and CEO of 7TM Pharma A/S and has a broad international experience within biotech / life science covering business development and licensing, management and financing. Prior to founding 7TM Pharma, Mette was part of the management team of NeuroSearch A/S responsible for business development and licensing. She started her career as patent agent and has over the years co-founded several biotech companies. Mette has been appointed to numerous board positions both in private and public companies. Mette Kirstine Agger graduated as biologist from the University of Copenhagen and has an MBA. Mette is a board member of Cydan Development, Psioxus, scPharmaceuticals, Thesan Pharmaceuticals and Veloxis.
Dorothy A. Coleman is the executive vice president and chief financial officer for Excellus BlueCross BlueShield and its parent corporation, The Lifetime Healthcare Companies, headquartered in Rochester, New York. A 30-year veteran of the health care industry, Ms. Coleman was CFO of Blue Cross and Blue Shield of Rhode Island before joining The Lifetime Healthcare Companies in 2011. Before Rhode Island, she was with UnitedHealthcare, Cigna, and a hospital in California. Ms. Coleman holds certified public accountant licenses in New York and Arizona. She studied Finance at Arizona State University and has a BS in Accounting from the University of Phoenix. She currently is pursuing an Executive MBA from the University of Rochester Simon School of Business.
Mr. Abhay Gandhi leads Sun Pharma’s North American Business as its chief executive officer comprising USA & Canada. The North American Business contributes 50% of Sun Pharma’s consolidated revenues. Abhay joined Sun Pharma in its marketing function and has spent over two decades in various executive roles of increasing responsibility. During his tenure, he held several key and critical positions in India Business and Emerging Markets. He was the head of Emerging Markets until March 2012, wherein he successfully built Sun Pharma’s business presence in the key Emerging Markets. From 2012 until 2016, he was the CEO – India & sub-continent business. His leadership enabled the India Business to grow over threefold in revenue to over US$ 1.1 billion within a short span of three years while jumping in Rank from #4 to #1. Abhay successfully integrated the Ranbaxy business with Sun Pharma after its acquisition and has established a track record of consistent success through focus on execution.
Abhay’s energy, operational excellence, strategic and vision enables him to spearhead the growth of Sun Pharma’s business in North America.
He is a Chemistry graduate from Mumbai University with a Degree in Management from the NMIMS and Diploma in Finance from the ICFAI. Abhay has over 30 years’ professional work experience, out of which 27 years have been in the pharmaceutical industry. Abhay is based in in New Jersey. He spends free time with his wife and two children.
Jack A. Khattar is the founder of Supernus Pharmaceuticals (NASDAQ:SUPN) and has served as president and chief executive officer and director since 2005. From 1999 to 2005, Mr. Khattar served in various positions, including board member, president and CEO of Shire Laboratories Inc., the drug delivery subsidiary of Shire plc. Prior to that, Mr. Khattar served as an executive officer and the chairman of the management committee at CIMA, a drug delivery company where he was also responsible for business development, corporate alliances and strategic planning. Prior to joining CIMA in 1995, Mr. Khattar held several marketing and business development positions at Merck & Co., Novartis, Playtex, and Kodak in various locations, including the United States, Europe and the Middle East. He served as a director of Rockville Economic Development Inc. from 2003 until 2013. He currently serves on the board of directors of Prevacus, Inc., a privately-held pharmaceutical company. Mr. Khattar earned his degrees in Marketing, with a BBA from American University of Beirut and an MBA from the Wharton School of the University of Pennsylvania.
Kush M. Parmar, M.D., PhD is a Partner at 5AM Ventures, a leading early stage venture capital firm focused on the life sciences. Before joining 5AM he was at Harvard Medical School, where he was an NIH-sponsored M.D./PhD physician scientist fellow in the joint Harvard-MIT Health Sciences and Technology Program. Dr. Parmar currently serves as a director or observer on the boards Arvinas, Audentes, Cleave, Novira, Pulmatrix and scPharmaceuticals. He previously served as board observer for Envoy (acquired by Takeda) and Achaogen (NASDAQ: AKAO). He is a member of the scientific advisory board of the Grace Wilsey Foundation and is a fellow of the society of Kauffman fellows. Before joining 5AM, Dr. Parmar completed clinical clerkships at the Massachusetts General & Brigham and Women’s Hospitals, attended courses at Harvard Business School and consulted for an oncology startup. Dr. Parmar’s PhD work at Harvard focused on cardiovascular biology and was published in The Journal of Clinical Investigation and the Journal of Biological Chemistry, among others. At Princeton University, Dr. Parmar worked on developmental genetics with Nobel Prize winner Eric F. Wieschaus. He also founded a non-profit international development organization, the Cruz Blanca Initiative. He holds an A.B. in Molecular Biology and Medieval Studies from Princeton University, a PhD in Experimental Pathology from Harvard University, and an M.D. from Harvard Medical School.
is the founding chairman CEO of WellPoint, the nation’s largest health benefits company by membership. WellPoint serves over 36 million medical members and has annualized revenues of $60 billion. He is currently the Judge Robert Maclay Widney chair and professor at the University of Southern California and is a senior advisor to TPG Capital, a private equity firm
Schaeffer is active on the boards of numerous businesses, philanthropic and professional organizations. He received the inaugural USC Sol Price Award for his lifetime achievements as a business leader, policy expert and philanthropist. He was the Regent’s Lecturer at the University of California at Berkeley, a Gilbert Fellow at Princeton, and a Williams Fellow at RAND. He is a member of the Institute of Medicine of the National Academy of Sciences. A native of Evanston, Illinois, he is a graduate of Princeton University.
Schaeffer and his wife, the former Pamela Sidford, have two children.
Jonathan T. Silverstein, J.D., is a partner and a co-head of global private equity at OrbiMed. Mr. Silverstein joined OrbiMed in 1999 to focus on private equity and structured transactions in small capitalization public biotechnology and medical device companies. Mr. Silverstein was previously a director of life sciences in the investment banking department at Sumitomo Bank. For the last five years (2012 to 2016) Forbes® magazine named Mr. Silverstein one of the top 100 venture capitalists in the world when it placed him on the “Forbes Midas List”. Mr. Silverstein has a J.D. and an M.B.A. from the University of San Diego, and a B.A. in Economics from Denison University.